Search results
Results from the WOW.Com Content Network
The first medical use of fumaric acid was described in 1959 by Walter Schweckendiek, a German chemist, [15] and was a topical formulation for psoriasis. The Swiss company Fumapharm eventually brought Fumaderm, an oral formulation of dimethyl fumarate (along with some monoesters) to market for psoriasis in Germany in 1994. [16] [17] [18]
It is recommended to name the SVG file “Psoriasis Treatment and DDx.svg”—then the template Vector version available (or Vva) does not need the new image name parameter. Summary Description Psoriasis Treatment and DDx.pdf
Fumaric acid was developed as a medicine to treat the autoimmune condition psoriasis in the 1950s in Germany as a tablet containing 3 esters, primarily dimethyl fumarate, and marketed as Fumaderm by Biogen Idec in Europe. Biogen would later go on to develop the main ester, dimethyl fumarate, as a treatment for multiple sclerosis.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code
Original file (1,275 × 1,650 pixels, file size: 20 KB, MIME type: application/pdf) This is a file from the Wikimedia Commons . Information from its description page there is shown below.
Original file (1,650 × 1,275 pixels, file size: 23 KB, MIME type: application/pdf) This is a file from the Wikimedia Commons . Information from its description page there is shown below.
PUVA (psoralen and UVA) is an ultraviolet light therapy treatment for skin diseases: vitiligo, eczema, psoriasis, graft-versus-host disease, mycosis fungoides, large plaque parapsoriasis, and cutaneous T-cell lymphoma, using the sensitizing effects of the drug psoralen.
"Pain ladder", or analgesic ladder, was created by the World Health Organization (WHO) as a guideline for the use of drugs in the management of pain. Originally published in 1986 for the management of cancer pain , it is now widely used by medical professionals for the management of all types of pain .